^
    2d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    2d
    μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia. (PubMed, Med)
    μPharma provides rapid (4-h assay), accurate, and automated prediction of drug sensitivity at single-cell resolution using minimal clinical samples, potentially enabling same-day precision oncology decision-making.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • dasatinib
    3d
    Clinical Observation of Allogeneic Hematopoietic Stem Cell Transplantation in Children with High-Risk T-cell Acute Lymphoblastic Leukemia (ChiCTR2600117387)
    P=N/A, N=20, Completed, Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital
    New trial
    3d
    A single-arm, open-label phase I clinical study on the safety and efficacy of U69 in the treatment of refractory/relapsed T-lymphoblastic leukemia/lymphoma (T-ALL /LBL) (ChiCTR2500114272)
    P1, N=18, Not yet recruiting, The First Affiliated Hospital of Soochow University; Shanghai Youkadi Biomedical Technology Co., Ltd
    New P1 trial
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    3d
    Targeted Sensitization of Leukemic T-cells to Anticancer Drugs by SIRT1 Agonist SRT-1720. (PubMed, Anticancer Res)
    SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity.
    Journal
    |
    SIRT1 (Sirtuin 1)
    |
    cisplatin • Ibrance (palbociclib) • everolimus • bortezomib • doxorubicin hydrochloride • bleomycin • ABT-737 • MG132 • barasertib (AZD1152)
    4d
    MicroRNAs as potential prognostic biomarkers in acute lymphoblastic leukemia: a systematic review, meta-analysis, and bioinformatics study. (PubMed, Syst Rev)
    These findings support miRNAs as valuable prognostic biomarkers for ALL with potential for personalized therapy. The context-dependent role of these miRNAs highlights the need for confirmation through large, multicenter trials. The constructed ceRNA network provides useful insights into their regulatory mechanisms, opening new directions for therapeutic strategies.
    Retrospective data • Journal
    |
    MIR210 (MicroRNA 210) • MIR335 (MicroRNA 335)
    5d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    5d
    Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (clinicaltrials.gov)
    P1, N=13, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Aug 2025 | Trial primary completion date: May 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    flotetuzumab (MGD006)
    6d
    Targeting the Notch receptor dimerization domain to inhibit Notch signalling-A new avenue of therapeutics. (PubMed, FEBS J)
    They show that the peptide inhibitors are specific to a Notch receptor paralogue. The possible biological and therapeutic consequences are discussed.
    Journal
    |
    NOTCH1 (Notch 1)
    6d
    Cannabidiol Regulates CD47 Expression and Apoptosis in Jurkat Leukemic Cells Dependent upon VDAC-1 Oligomerization. (PubMed, Pharmaceuticals (Basel))
    Overall, we conclude that CBD downregulates CD47 expression and induces apoptosis involving VDAC-1 oligomerization. Furthermore, they also suggest that CBD's pro-apoptotic effects on primary human T cells should also be monitored if it is used as an anti-cancer adjuvant or neo-adjuvant therapeutic in cancer patients.
    Journal
    |
    CD47 (CD47 Molecule)
    6d
    Profiles of Growth Factors Secreted by In Vitro-Stimulated Paediatric Acute Leukaemia Blasts of Myeloid and Lymphoid Origin. (PubMed, Int J Mol Sci)
    Lineage-specific responses may be exploitable for targeted therapeutic approaches for distinct AL types. This study is the first to comprehensively assess the extracellular secretion of multiple GFs by paediatric AL cells in cultures using a Bio-Plex multiplex immunoassay.
    Preclinical • Journal
    |
    VEGFA (Vascular endothelial growth factor A) • CSF2 (Colony stimulating factor 2) • FGF (Fibroblast Growth Factor)
    6d
    MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, King Hussein Cancer Center
    New trial
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)